PRZOOM - /newswire/ -
Basel, Switzerland, 2008/12/15 - Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, announces an expansion of its research informatics collaboration with the global biopharmaceutical company UCB.
The two companies have collaborated since 2006 with a focus on enhancing the management of drug target and biomarker discovery data using the Genedata Phylosopher® and Genedata Expressionist® platforms.
The collaboration has been renewed and expanded and now also supports UCB’s biologics and lead-finding activities in the fields of central nervous system disorders and autoimmune and inflammatory disorders research conducted in the UK and Belgium.
The extended collaboration aims to further expand the established platform from target discovery functionalities to lead generation support. For this advance, the Genedata Phylosopher platform is now additionally being used for storing proprietary drug candidate information produced by UCB’s biologics discovery efforts. As such, the Phylosopher database now relates therapeutic targets to protein-based drug leads, as well as sequence-based biologics reference data. This allows scientists to make better and faster drug discovery and development decisions.
In addition, Genedata Expressionist functionalities have been expanded to include data from much of UCB’s molecular profiling technology portfolio. Scientists can now review and explore multiple data types in one space to make better and faster decisions.
“Our decision to combine Genedata’s software products with our in-house customized software has been driven by the trust that we have developed in their established product line. This marriage has allowed us to leverage capabilities of both systems to support the generation of scientific insight more efficiently,” said Dr. Phil Scordis, UCB Senior Group Leader, Informatics. “We are pleased that we can work with Genedata as an experienced partner. It has been important to the progress of these activities that Genedata’s software products can be easily integrated into our existing infrastructure.”
“We are proud that we have been able to expand and diversify our relationship with UCB, a leading global biopharmaceutical company,” said Dr. Othmar Pfannes, CEO of Genedata. “Our collaboration with UCB is an excellent showcase of how Genedata’s products can meet a company’s specific needs for both small and large molecule drug discovery.”
Genedata (genedata.com) develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata’s solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high throughput technologies. Our solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan.
UCB, Brussels, Belgium (ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 12,000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB).